MaxCyte Shares Owned By Insiders vs. Number Of Employees
| MXCT Stock | USD 3.55 0.10 2.90% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.8851 |
|
|
For MaxCyte profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MaxCyte to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MaxCyte utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MaxCyte's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MaxCyte over time as well as its relative position and ranking within its peers.
MaxCyte |
MaxCyte's Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MaxCyte. If investors know MaxCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MaxCyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 0.437 | Quarterly Revenue Growth 0.02 | Return On Assets (0.11) | Return On Equity (0.16) |
The market value of MaxCyte is measured differently than its book value, which is the value of MaxCyte that is recorded on the company's balance sheet. Investors also form their own opinion of MaxCyte's value that differs from its market value or its book value, called intrinsic value, which is MaxCyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MaxCyte's market value can be influenced by many factors that don't directly affect MaxCyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MaxCyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if MaxCyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MaxCyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
MaxCyte Number Of Employees vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining MaxCyte's current stock value. Our valuation model uses many indicators to compare MaxCyte value to that of its competitors to determine the firm's financial worth. MaxCyte is rated below average in shares owned by insiders category among its peers. It is rated below average in number of employees category among its peers creating about 95.97 of Number Of Employees per Shares Owned By Insiders. Comparative valuation analysis is a catch-all technique that is used if you cannot value MaxCyte by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.MaxCyte Number Of Employees vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
MaxCyte |
| = | 1.49 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
MaxCyte |
| = | 143 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
MaxCyte Number Of Employees vs Competition
MaxCyte is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 19,043. MaxCyte maintains roughly 143 in number of employees contributing less than 1% to equities under Health Care industry.
MaxCyte Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in MaxCyte, profitability is also one of the essential criteria for including it into their portfolios because, without profit, MaxCyte will eventually generate negative long term returns. The profitability progress is the general direction of MaxCyte's change in net profit over the period of time. It can combine multiple indicators of MaxCyte, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -48.3 M | -45.9 M | |
| Income Before Tax | -37.9 M | -36 M | |
| Total Other Income Expense Net | 10.4 M | 10.9 M | |
| Net Loss | -37.9 M | -36 M | |
| Income Tax Expense | 4 M | 4.2 M | |
| Net Interest Income | 9.4 M | 9.9 M | |
| Net Loss | -37.5 M | -35.6 M | |
| Net Loss | -21.2 M | -22.3 M | |
| Interest Income | 9.5 M | 10 M | |
| Non Operating Income Net Other | 4.4 M | 4.6 M | |
| Change To Netincome | 13.7 M | 14.4 M | |
| Net Loss | (0.37) | (0.35) | |
| Income Quality | 0.57 | 0.81 | |
| Net Income Per E B T | 0.97 | 1.10 |
MaxCyte Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on MaxCyte. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of MaxCyte position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the MaxCyte's important profitability drivers and their relationship over time.
Use MaxCyte in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MaxCyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MaxCyte will appreciate offsetting losses from the drop in the long position's value.MaxCyte Pair Trading
MaxCyte Pair Trading Analysis
The ability to find closely correlated positions to MaxCyte could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MaxCyte when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MaxCyte - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MaxCyte to buy it.
The correlation of MaxCyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MaxCyte moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MaxCyte moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MaxCyte can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your MaxCyte position
In addition to having MaxCyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Funds Thematic Idea Now
Tech Funds
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.